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DOI: http://dx.doi.org/10.1016/j.hemonc.2015.06.005OBJECTIVE/BACKGROUND: The most common indication for high-dose chemotherapy (HDC) and
autologous hematopoietic cell transplantation (AHCT) in the 1990s was breast cancer. Several randomized
trials and a more recent meta-analysis failed to show a survival benefit for AHCT in metastatic breast
cancer (MBC); however, they demonstrated a better-than-expected 10-year to 15-year survival in 5–15%
of patients. We thus evaluated the long-term results of treatment with HDC and AHCT in MBC at our
institution.
METHODS: From 1984 to 2000, 285 patients underwent AHCT for MBC. The patient characteristics were
collected through the Cleveland Clinic, United Transplant Database. A retrospective review of the medical
records of the long-term surviving breast-cancer patients treated with HDC and AHCT was conducted.
RESULTS: With a median follow-up of 169 months, 34 (12%) remain alive. Of the 251 patients who died,
218 (87%) died of metastatic disease. A comparison by age (<50 years and >50 years) and hormonal status
did not demonstrate any differences in relapse (p = .33 and p = .32, respectively) or survival (p = .13 and
p = .42). Of the 34 long-term survivors, sufficient data were available on 28 patients, and further evaluation
revealed that the majority had a primary or locally recurrent oligometastatic disease.
CONCLUSION: This retrospective evaluation of patients who underwent AHCT for MBC demonstrates long-
term survival in a small subset of patients, primarily those with primary or recurrent oligometastatic disease.
Oligometastatic breast cancer is a distinct entity within MBC, which may be curable with multimodality
therapy. We thus conclude there remains no overall-survival benefit to HDC in MBC.
KEYWORDS: Autologous hematopoietic cell transplant; High-dose chemotherapy; Oligometastatic breast cancerDespite advances in the diagnosis and treat-ment for breast cancer over the last severaldecades, metastatic breast cancer (MBC)
is the leading cause of cancer death in women in
developed countries.1,2 MBC is a heterogeneous dis-
ease that may range from solitary metastatic lesions
to diffuse multiorgan involvement. Preclinical studiespublished in the early 1980s demonstrated a steep
dose–response effect predicting for greater cytotoxic-
ity with increasing dose intensity of antitumor agents,
such as alkylating agents and antimetabolites.3 These
data served as the basis for the use of high-dose
chemotherapy (HDC) with autologous hematopoietic
cell transplantation (AHCT) for a variety of solid115
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tumors. Several nonrandomized studies in the
mid-1980s and early 1990s suggested a prolonged
survival for women with breast cancer who received
HDC with AHCT.4–6 These trials were subject to
biases, including patient selection,7 and subsequent
randomized Phase III trials were performed to
address the role of HDC in MBC. Owing to poor
accrual, these trials were relatively small, and did
not show a signiﬁcant survival advantage for HDC
compared to conventional chemotherapy.8–12 Many
of these trials were underpowered to detect realistic
differences; however, a recently published
meta-analysis from the six MBC randomized trials
comparing HDC with conventional therapy without
stem-cell support conﬁrmed a lack of signiﬁcant sur-
vival advantage and failed to identify any subset of
patients who beneﬁted from this approach.
Regardless, many of these trials8–12 demonstrate a
better-than-expected 10-year to 15-year progression-
free and overall survival (OS) occurring in a small
subset (5–15%) of patients. There thus remains con-
troversy as to whether speciﬁc subsets of MBC
patients may beneﬁt from HDC. These data
prompted us to evaluate the long-term results and
the survivors of treatment with HDC and AHCT
in MBC at our institution.MATERIALS AND METHODS
Patients
Four hundred ninety-one patients underwent HDC
followed by AHCT for breast cancer from 1984 to
2000 at the Cleveland Clinic, Taussig Cancer
Institute. Among these, 285 were diagnosed as having
metastatic stage IV disease according to the American
Joint Committee on Cancer staging guidelines prior to
2000. All patientsmet theminimal criteria for eligibility
to proceedwithHDCandAHCTper our standard and
protocol guidelines. All study patients provided a signed
informed consent, and were treated on protocols
approved by the institutional review board.
Transplant regimens
STAMP-V (cyclophosphamide [Cy] given by intra-
venous infusion at 1500 mg/m2 daily · 4 days; carbo-
platin, 200 mg/m2 · 4 days; and thiotepa [TT],
125 mg/m2 · 4 days), n = 177, was the predominant
preparative regimen given prior to AHCT. Other
conditioning regimens included busulfan (1 mg/kg
orally every 6 h · 16 doses) and Cy (60 mg/kg
intravenous infusion · 2 days), n = 54; STAMP-I
(Cy, given intravenously at 1875 mg/m2 · 3 days; cis-
platin, 55 mg/m2 · 3 days; and bis-chloronitrosourea(BCNU), 600 mg/m2 given for one dose), n = 26;
and either high-dose TT or BCNU alone (n = 28).
Study design
The patient clinical and transplant characteristics
were collected through the Cleveland Clinic, Taussig
Cancer Institute, United Transplant Database. A ret-
rospective review of the medical records of the long-
term surviving breast-cancer patients treated with
HDC and AHCT was also conducted. The data col-
lected included patient demographics, characteristics
of the primary and recurrent tumor, axillary nodal sta-
tus, prior adjuvant chemotherapy, hormone-receptor
status, extent of metastatic disease, and patient out-
come. The combined hormone-receptor status was
considered negative if both estrogen receptors (ERs)
and progesterone receptors (PRs) were negative, and
positive if either one or both were positive.
Information was not available regarding the human
epidermal-growth-factor receptor 2 (HER2) status.
Statistical analysis
Three outcomes were assessed: relapse, OS, and
relapse-free survival (RFS). Events corresponding to
these three outcomes were relapse, all-cause mortality,
and relapse or all-cause mortality, respectively. The
outcomes were calculated from the date of transplant
to the date of the event or the date of the last follow-
up. Because age and ER/PR status are often prognos-
tic factors in breast cancer, the outcomes were com-
pared by age (<50 years and 50 years) and
ER/PR status (positive vs. negative) using log-rank
tests. A continuous variable was calculated for years
since the ﬁrst study transplant to account for potential
changes in outcomes over the study duration. Cox
proportional hazards analysis was used to identify sig-
niﬁcant prognostic factors. For the multivariable anal-
ysis, a stepwise-selection procedure was used with a
variable entry criterion of p  .10 and a variable
retention criterion of p  .05. The Cox results are
summarized as the hazard ratio (HR) and 95% conﬁ-
dence interval (CI) for the HR. The data were
analyzed using the SAS software (SAS Institute,
Inc., Cary, NC, USA). All statistical tests were two
sided, and p  .05 was used to indicate statistical
signiﬁcance.RESULTS
The patient and transplant characteristics are shown
in Table 1. The median age was 44 years (range:
24–65 years), and the overwhelming majority was
female (99%). The majority of patients had aHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015
Table 1. Patient and transplant characteristics.
Variable N (%)
Gender
Female 282 (99)
Male 3 (1)
Race (n = 240)
White 230 (96)
Black 10 (4)
Age at transplant (years)
Mean € SD 44 € 7
Median (range) 44 (24–65)
Karnofsky performance status (n = 273)
80 7 (3)
90 255 (93)
100 11 (4)
Number of prior chemotherapy regimens
1 86 (30)
2 155 (54)
3 34 (12)
4 7 (3)
5 3 (1)
Prior radiation therapy
Yes 159 (56)
No 126 (44)
Months from diagnosis to transplant
Mean € SD 42 € 34.5
Median (range) 33.2 (3–201)
Disease status at transplant
CR 155 (54)
PR 122 (43)
Relapsed/refractory 8 (3)
ER/PR status (n = 242)
Positive 161 (67)
Negative 81 (33)
Table 1. (Continued).
Variable N (%)
Number of positive nodes (n = 261)
Mean € SD 16 € 8
Median (range) 14 (1–42)
Cell source
PBSC 235 (83)
BM 35 (12)
PBSC + BM 15 (5)
Preparative regimen
STAMP-V 177 (62)
Bu/Cy 54 (19)
Cis/Cy/BCNU 26 (9)
Other 28 (10)
CD34 + dose · 106/kg (n = 186)
Mean € SD 4.91 € 4.22
Median (range) 3.24 (.37–29.71)
Patient status at follow-up
Alive 34 (12)
Dead 251 (88)
Secondary malignancy
Yes 4 (1)
No 281 (99)
Cause of death (n = 251)
Relapse 218 (87)
Infection 4 (2)
Pulmonary toxicity 3 (1)
Cardiac 3 (1)
Secondary malignancy 2 (.8)
VOD 2 (.8)
CNS bleed 1 (.4)
Unknown 18 (7)
BCNU = bis-chloronitrosourea; BM = bone marrow; Bu/Cy = busulfan/cyclophosphamide;
Cb = carboplatin; Cis = cisplatin; CNS = central nervous system; Cy = cyclophosphamide;
PBSC = peripheral-blood stem cell; TT = thiotepa; VOD = veno-occlusive disease.
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Table 2. Univariate model for relapse, relapse-free survival, and overall survival.
Variable Relapse Relapse-free survival Overall survival
HR 95% CI p HR 95% CI p HR 95% CI p
Sex
Male/female 0.75 .10–5.36 0.77 2.05 .65–6.42 0.22 2.36 .75–7.38 0.14
Race (N = 240)
Black/white 0.5 .22–1.13 0.1 0.61 .30–1.24 0.17 0.64 .30–1.35 0.24
Age at transplant (years)
50/<50 1.16 .86–1.57 0.33 1.2 .90–1.60 0.21 1.25 .94–1.67 0.13
Karnofsky performance status (N = 273)
Per 10-point increase 0.87 .49–1.55 0.64 0.79 .45–1.39 0.41 0.64 .36–1.15 0.14
Number of prior chemotherapy regimens
Per one increase 1.5 1.27–1.77 <.001 1.43 1.22–1.68 <.001 1.41 1.20–1.65 <.001
Prior radiation therapy
Yes/no 1.09 .84–1.42 0.5 1.07 .84–1.37 0.6 1.14 .88–1.46 0.31
Months from diagnosis to HCT
Per 12-month increase 1.02 .98–1.07 0.26 1.02 .98–1.06 0.36 1.03 .99–1.07 0.17
Disease status at transplant
Partial remission/CR 1.54 1.18–2.00 0.001 1.56 1.21–2.00 <.001 1.57 1.21–2.02 <.001
Relapsed/refractory/CR 1.73 .76–3.94 0.19 2.15 1.05–4.40 0.036 2.56 1.24–5.26 0.011
ER/PR status (N = 242)
Positive/negative 0.86 .64–1.16 0.32 0.95 .72–1.26 0.73 0.89 .66–1.18 0.42
Number of positive nodes (N = 261)
Per one node increase 1 .98–1.02 0.7 1 .98–1.02 0.78 1 .98–1.02 0.89
Cell source
BM/PBSC + BM 1.85 .90–3.81 0.09 2.38 1.22–4.63 0.011 2.45 1.23–4.87 0.011
PSC/PBSC + BM 1.31 .72–2.42 0.38 1.35 .75–2.43 0.31 1.38 .75–2.54 0.3
Preparative regimen
STAMP-V/other 0.68 .42–1.11 0.12 0.53 .35–.80 0.003 0.53 .35–.80 0.003
Bu/Cy/other 0.69 .40–1.20 0.19 0.55 .34–.89 0.015 0.67 .42–1.08 0.1
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Table 2. (Continued).
Variable Relapse Relapse-free survival Overall survival
HR 95% CI p HR 95% CI p HR 95% CI p
Cis/Cy/BCNU/other 0.44 .24–.84 0.011 0.33 .19–.59 <.001 0.34 .19–.60 <.001
Years since first transplant
Per 5-year increase 0.92 .73–1.16 0.47 0.81 .66–1.01 0.06 0.75 .61–.93 0.007
BCNU = bis-chloronitrosourea; BM = bone marrow; Bu = busulfan; CI = confidence interval; Cis = cisplatin; CR = complete remission; Cy = cyclophosphamide; ER = estrogen receptor;
HCT = hematopoietic cell transplantation; HR = hazard ratio; PBSC = peripheral-blood stem cell; PR = progesterone receptor.
Figure 1. Cumulative incidence of relapse after high-dose chemotherapy and autologous hematopoietic cell transplantation in (A) metastatic-
breast-cancer patients <50 years of age and 50 years of age, and (B) patients with estrogen-receptor/progesterone-receptor-positive and
estrogen-receptor/progesterone-receptor-negative tumors. ER = estrogen receptor; PR = progesterone receptor.
HIGH-DOSE CHEMOTHERAPY IN BREAST CANCER original research reportKarnofsky performance status of at least 90%. About
70% of the patients received more than one prior
chemotherapy regimen, which primarily consisted ofHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015the combination with Cy, Adriamycin, and
5-ﬂuorouracil; Cy, methotrexate, and 5-ﬂuorouracil;
or Adriamycin and Cy; and 56% had received prior119
Figure 2. Kaplan–Meier curve of overall survival after high-dose chemotherapy and autologous hematopoietic cell transplantation in (A)
metastatic-breast-cancer patients <50 years of age and 50 years of age, and (B) patients with estrogen-receptor/progesterone-receptor-positive
and estrogen-receptor/progesterone-receptor-negative tumors. ER = estrogen receptor; PR = progesterone receptor.
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were in a complete remission (CR) prior to HDC,
while 43% achieved a progesterone receptor and 3%
were relapsed or refractory prior to HDC. The major-
ity (83%) of the patients received peripheral-blood
stem cells (PBSCs), 12% received bone marrow
(BM), and 5% received a combination of both
PBSCs and BM. Approximately 62% of the patients
received STAMP, 19% busulfan/Cy, 9%
cisplatin/Cy/BCNU, and 10% other, including
single agent TT or BCNU. The median
CD34 + dose given to the patients was
3.24 · 106/kg (range: 0.37–29.71). The median
length of hospital stay was 21 days (range:
7–90 days). The median time after transplant to
reach an absolute neutrophil count >0.5 · 109/L
and platelet count >20 · 109/L was 11 days (range:8–48 days) and 13 days (range: 8–139 days),
respectively.
With a median follow-up of 169 months (range:
77–283 months) in survivors, 34 (12%) of these
patients remain alive. Of the 251 patients who died,
218 (87%) died of relapsed/metastatic disease.
Other causes of death included infectious or car-
diopulmonary etiologies. The incidence of death from
secondary malignancies was less than 1%. HER2 sta-
tus was unavailable in the majority of the patients, but
a comparison by age (<50 and  50) and hormonal
status did not demonstrate any signiﬁcant differences
in relapse (86% vs. 89%, p = .33 [Figure 1A] and
85% for ER/PR negative vs. 88% for ER/PR positive,
p = .32, respectively [Figure 1B]) or survival (16% vs.
8%, p = .13 [Figure 2A] and 18% vs. 14%, p = .42
[Figure 2B]) at 10 years.Hematol Oncol Stem Cell Ther 8(3) Third Quarter 2015
Table 3. Multivariable analysis for relapse, relapse-free survival, and overall survival.
Variable Relapse Relapse-free survival Overall survival
HR 95% CI p HR 95% CI p HR 95% CI p
Number of prior chemotherapy regimens
Per one increase 1.46 1.23–1.73 <.001 1.52 1.28–1.80 <.001 1.48 1.25–1.74 <.001
Disease status at transplant
Partial remission/CR 1.43 1.10–1.87 0.008 1.34 1.04–1.74 0.025 1.34 1.03–1.75 0.029
Relapsed/refractory/CR 1.71 .75–3.90 0.2 2.03 .99–4.17 0.054 2.66 1.29–5.49 0.008
Cell source
BM/PBSC + BM – 2.5 1.25–4.99 0.009 2.49 1.23–5.07 0.012
PSC/PBSC + BM 1.14 .63–2.06 0.67 1.17 .63–2.17 0.62
BM = bone marrow; CI = confidence interval; CR = complete remission; HR = hazard ratio; PBSC = peripheral-blood stem cell.
HIGH-DOSE CHEMOTHERAPY IN BREAST CANCER original research reportThe univariate prognostic factors were identiﬁed
for relapse, RFS, and OS (Table 2). Gender, race,
age, performance status, prior radiation therapy,
hormonal status, and nodal status were not found to
be prognostic factors for relapse or survival.
Each additional prior chemotherapy regimen was
associated with an increased risk for relapse, worse
RFS, and worse OS. The disease status at time of
transplant was associated with outcome:
compared to patients who underwent HDC after a
CR to prior therapy, patients with a partial remission
had a higher risk for relapse, and experienced
worse RFS and OS. Cell source (BM vs. PBSCs)
was also associated with worse RFS and OS. Years
since the ﬁrst study transplant was also a signiﬁcant
variable, with improved OS per 5-year increase
(Table 2).
In a multivariable analysis, additional prior
chemotherapy regimens, cell source, and poor disease
status at time of transplant remained prognostic for
worse outcome (Table 3). Time of transplant was
highly correlated with cell source (BM vs. PBSCs),
and thus became nonsigniﬁcant for OS. An additional
chemotherapy regimen prior to AHCT was associ-
ated with an increased risk for relapse (HR 1.5,
95% CI 1.2–1.7, p < .001), worse RFS (HR 1.4,
95% CI 1.2–1.6, p < .001), and worse survival (HR
1.4, 95% CI 1.2–1.6, p < .001). There was an
increased risk of relapse (HR 1.4, 95% CI 1.1–1.9,
p = .008), worse RFS (HR 1.5, 95% CI 1.1–1.9,
p = .003), and worse OS (HR 1.5, 95% CI 1.1–1.9,Hematol Oncol Stem Cell Ther 8(3) Third Quarter 2015p = .004) in the patients who had a PR compared
to CR prior to transplant. The patients with relapsed
or refractory disease had worse RFS and OS (HR 2.1,
95% CI 1.0–4.4, p = .038 and HR 2.7, 95% CI 1.3–
5.4, p = .008, respectively), but increased risk for
relapse was not signiﬁcant, p = .20. Data regarding
number and type of metastatic sites were not available
for the entire cohort, and thus could not be included
in the analysis.
Of the 34 long-term survivors identiﬁed, sufﬁcient
data from the medical record were available on
28 patients (Table 4). In this cohort of long-term sur-
vivors, 10 patients had metastatic disease at presenta-
tion, while 18 patients had recurrent metastatic
disease. Of the 10 patients with primary metastatic
disease, four patients had oligometastatic involvement
of the ipsilateral supraclavicular lymph node, which
would now be classiﬁed as stage IIIC disease by the
current American Joint Committee on Cancer staging
guidelines. Three patients had limited bone disease
and three had oligometastatic disease that had been
resected prior to HDC and AHCT. Of the
18 patients with recurrent metastatic disease, nine
had local recurrence at the site of the incision or chest
wall, and six had a single site of recurrence primarily
in the lung or locoregional lymph nodes, also classiﬁed
as primarily oligometastatic disease. Most of these
lesions were surgically resected prior to HDC and
AHCT. Of the remaining three patients, one had
recurrent lesions in the liver, one had bilateral breast
recurrence, and one had recurrence in the lung with121
Table 4. Patient characteristics among long-term survivors.
Patient Age ER/PR status Site of metastatic disease
1 36 Positive Primary metastatic disease involving bone marrow
2 44 Positive Recurrent liver lesion
3 29 Positive Recurrent axillary and intramammary lymph nodes
4 48 Positive Recurrent single lung nodule
5 38 Negative Recurrent supraclavicular lymph node
6 42 Unknown Recurrent single hilar mass
7 51 Unknown Recurrent single lung nodule
8 43 Negative Recurrent infraclavicular lymph node
9 38 Negative Recurrent supraclavicular lymph node
10 39 Positive Recurrent chest-wall lesion
11 44 Positive Recurrent lesion at primary site
12 42 Positive Recurrent chest-wall lesion
13 41 Unknown Recurrent chest-wall lesion
14 45 Negative Recurrent lesion at primary site and supraclavicular lymph node
15 48 Positive Recurrent local axillary lymph node
16 44 Positive Recurrent lesion at incision site
17 39 Negative Recurrent chest-wall lesion
18 43 Negative Recurrent lesion at incision site and locally
19 32 Positive Recurrent bilateral breast lesions
20 42 Negative Primary metastatic disease to the supraclavicular lymph node
21 44 Unknown Primary metastatic disease to the supraclavicular lymph node
22 48 Negative Primary metastatic disease to the supraclavicular lymph node
23 48 Unknown Primary metastatic disease to the supraclavicular lymph node
24 44 Unknown Primary metastatic disease to the ovary (single site)
25 53 Positive Primary metastatic disease to solitary lung nodule
26 59 Negative Primary metastatic disease to solitary lung nodule
27 44 Positive Primary metastatic disease involving bone marrow
28 37 Positive Primary metastatic disease to thoracic spine (T9) and rib
122
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which data were available received systemic
chemotherapy (Cy, Adriamycin, and 5-ﬂuorouracil;
Cy, methotrexate, and 5-ﬂuorouracil; or Adriamycin
and Cy) prior to HDC and AHCT. Long-term sur-
vival was not associated with age or hormonal status.
The median age was 43 years (range: 29–59 years),
and 13 patients were ER/PR positive, eight patients
were ER/PR negative, and hormonal status was
unknown in seven patients.DISCUSSION
While the use of HDC and AHCT has largely been
abandoned in the United States, several recent long-
term follow-up studies, such as this one, question its
role for select populations.13–15 A recently published
registry study of 415 patients from the Italian
Group of Bone Marrow and Hematopoietic Stem
Cell Transplantation and Cellular Therapy demon-
strated a signiﬁcant group (32%) of patients survivingHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015
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10 years,15 suggesting a role for HDC and AHCT in
delaying disease progression and potentially curing a
subset of patients with MBC. Our current retrospec-
tive evaluation of patients who underwent HDC and
AHCT for MBC at our institution also demonstrates
long-term survival in a small subset of MBC patients,
which we found to be predominantly those with pri-
mary or recurrent oligometastatic disease.
Our current study has several limitations, includ-
ing the retrospective nature of the analysis and the
limited registry data available on the patients.
HER2 status was unavailable on the majority of
patients, and we were unable to accurately assess the
extent of metastatic disease in the entire cohort given
the limited medical records. Our analysis is also sub-
ject to bias in patient selection and staging similar to
previous studies. A portion of our long-term survivors
were found to have supraclavicular nodal metastasis,
which has previously been shown to have signiﬁcantly
better outcomes compared to patients with other
metastatic disease, with survival similar to that of
IIIB, and thus has been reclassiﬁed as stage IIIC since
2002.16,17 Despite this, similar to past studies, we
show in this current analysis a longer-than-expected
long-term survival in a subset of patients, regardless
of age or hormonal status in MBC. However, these
long-term survivors were predominantly patients with
primary or recurrent oligometastatic breast cancer.
Previous studies have suggested that oligometa-
static breast cancer is a distinct subgroup with long-
term prognosis that is superior to MBC.18–20
Oligometastatic breast cancer comprises about 1–
10% of newly diagnosed MBC patients, and is poten-
tially curable.18,21 While patients with MBC are gen-
erally deﬁned by chemosensitivity, the improved
prognosis of oligometastatic disease is distinct due
to the low-tumor burden at the time of metastatic
recurrence. The role for systemic therapy, however,
is underscored by the fact that all patients with oligo-
metastatic disease treated with local therapy alone will
inevitably die from disease progression due to micro-
metastatic disease.
Data on the use of HDC and AHCT as adjuvant
therapy after local treatment for oligometastatic breastHematol Oncol Stem Cell Ther 8(3) Third Quarter 2015cancer are limited and have only been evaluated in one
prospective trial evaluating 60 patients.19 The trial
included patients with limited bone metastases, but
excluded patients with brain and liver metastases. At
5 years, RFS and OS were 52% and 62%, respectively.
HER2 overexpression, number of metastatic sites,
and increased axillary nodal ratio were found to be
important prognostic factors for worse outcome, and
a prognostic model for risk of relapse after AHCT
was proposed for this oligometastatic population.
A series of consecutive trials,22–24 the majority of
which had locoregional recurrence alone, evaluated
standard-dose anthracycline-based and docetaxel-
based adjuvant chemotherapy for systemic treatment
of single-site metastases. In the three anthracycline-
based trials, 20-year disease-free survival (DFS) and
OS reached 26%, while in the docetaxel-based trial,
5-year DFS and OS were 34% and 59%, respectively.
Compared with historical controls of patients who did
not receive chemotherapy after local therapy, patients
at the same institution who did not receive systemic
treatment had signiﬁcantly worse outcomes with a
15-year DFS rate of only 3%. This underscores the
fact that systemic chemotherapy remains a critical
component to the successful control of microscopic
diseases and a key to a potential cure in patients with
oligometastatic breast cancer.
The long-term survival after HDC and AHCT for
MBC is still rare, and there remains no demonstrable
beneﬁt to transplant. The 10–15% of long-term sur-
vivors seen in this study represent a population of pri-
marily oligometastatic or a locally recurrent disease,
which may otherwise be curable with other multi-
modality therapies.CONFLICTS OF INTEREST
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